Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Rheumatol Int ; 44(11): 2659-2668, 2024 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-38914777

RESUMO

Following the market authorization of interleukin (IL)-17 inhibitors, a growing number of cases of IL-17 inhibitor-induced paradoxical psoriasis (PsO) have been reported. Our objectives were to present two cases of IL-17 inhibitor-induced paradoxical PsO and to systematically review the literature for similar cases, summarizing and presenting the relevant data. A systematic literature review of previously presented cases of paradoxical PsO induced by IL-17 inhibitors was conducted. We presented two patients with axial spondyloarthritis (axSpA) and paradoxical PsO induced by secukinumab (SEC). One patient's psoriatic lesions responded well to adjuvant topical treatment, while the other patient required a combination of topical treatment and cyclosporine Α for successful treatment. SEC was continued in both cases. We also identified 35 patients with IL-17 inhibitor-induced paradoxical PsO in the literature review. The most frequent types of paradoxical PsO were palmoplantar pustular and plaque PsO, while the median latency period was 11 weeks. Approximately one-third of patients continued IL-17 inhibitor treatment with adjunctive therapy, primarily topical, which produced satisfactory results in most patients. Almost two-thirds of the patients discontinued the IL-17 inhibitor, with the majority of patients switching to another biological agent with a different mechanism of action or initiating other systemic antipsoriatic treatments, resulting in mainly satisfactory outcomes. Therefore, paradoxical PsO induced by IL-17 inhibitors appears to respond well in both patients who continue IL-17 inhibitors with adjunctive treatment and those who discontinue IL-17 inhibitors while switching to a different class of biological agent or initiating other systemic antipsoriatic treatments.


Assuntos
Anticorpos Monoclonais Humanizados , Interleucina-17 , Psoríase , Humanos , Psoríase/tratamento farmacológico , Psoríase/induzido quimicamente , Interleucina-17/antagonistas & inibidores , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , Masculino , Adulto , Feminino , Espondiloartrite Axial/tratamento farmacológico , Espondiloartrite Axial/induzido quimicamente , Pessoa de Meia-Idade , Resultado do Tratamento
3.
Cureus ; 16(9): e68496, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39364452

RESUMO

Meckel's diverticulum is a common congenital anomaly of the gastrointestinal tract and is often asymptomatic. This case report details the diagnosis and treatment of small bowel obstruction particularly in a segment of the jejunum in a 41-year-old woman due to Meckel's diverticulum. The patient presented with diffuse abdominal pain and bloating. Imaging and clinical evaluation revealed signs of ileus, leading to an exploratory laparotomy. Intraoperative findings included a mass consistent with Meckel's diverticulum causing adhesion and torsion of the jejunum. The surgical intervention involved adhesiolysis and segmental enterectomy with side-to-side anastomosis. Histopathological analysis confirmed Meckel's diverticulum with ectopic gastric mucosa. The patient had an uneventful postoperative recovery and was discharged on the seventh postoperative day.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa